These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 25953090)

  • 21. S100A14 is a novel independent prognostic biomarker in the triple-negative breast cancer subtype.
    Ehmsen S; Hansen LT; Bak M; Brasch-Andersen C; Ditzel HJ; Leth-Larsen R
    Int J Cancer; 2015 Nov; 137(9):2093-103. PubMed ID: 25912829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of invasive micropapillary and triple negative invasive ductal carcinoma of the breast.
    Chen HL; Ding A
    Breast; 2015 Dec; 24(6):723-31. PubMed ID: 26392199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlates of serum lipids and lipoproteins in Congolese patients with arterial hypertension.
    Lepira FB; M'Buyamba-Kabangu JR; Kayembe KP; Nseka MN
    Cardiovasc J S Afr; 2005; 16(5):249-55. PubMed ID: 16307156
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regulator of G protein signaling 20 correlates with clinicopathological features and prognosis in triple-negative breast cancer.
    Li Q; Jin W; Cai Y; Yang F; Chen E; Ye D; Wang Q; Guan X
    Biochem Biophys Res Commun; 2017 Apr; 485(3):693-697. PubMed ID: 28237701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Peripheral Blood Neutrophil-To-Lymphocyte Ratio Is Superior to the Lymphocyte-To-Monocyte Ratio for Predicting the Long-Term Survival of Triple-Negative Breast Cancer Patients.
    Jia W; Wu J; Jia H; Yang Y; Zhang X; Chen K; Su F
    PLoS One; 2015; 10(11):e0143061. PubMed ID: 26580962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platinum-based chemotherapy in triple-negative advanced breast cancer.
    Villarreal-Garza C; Khalaf D; Bouganim N; Clemons M; Peña-Curiel O; Baez-Revueltas B; Kiss A; Kassam F; Enright K; Verma S; Pritchard K; Myers J; Dent R
    Breast Cancer Res Treat; 2014 Aug; 146(3):567-72. PubMed ID: 25001611
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of pegylated liposomal doxorubicin-based adjuvant chemotherapy in patients with stage I-III triple-negative breast cancer.
    Lien MY; Liu LC; Wang HC; Yeh MH; Chen CJ; Yeh SP; Bai LY; Liao YM; Lin CY; Hsieh CY; Lin CC; Li LY; Lin PH; Chiu CF
    Anticancer Res; 2014 Dec; 34(12):7319-26. PubMed ID: 25503167
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
    Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
    Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
    Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
    BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inflammatory TNBC Breast Cancer: Demography and Clinical Outcome in a Large Cohort of Patients With TNBC.
    Biswas T; Efird JT; Prasad S; James SE; Walker PR; Zagar TM
    Clin Breast Cancer; 2016 Jun; 16(3):212-6. PubMed ID: 26988771
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple-negative and non-triple-negative breast cancer.
    Bahhnassy A; Mohanad M; Shaarawy S; Ismail MF; El-Bastawisy A; Ashmawy AM; Zekri AR
    Mol Med Rep; 2015 Jul; 12(1):851-64. PubMed ID: 25824321
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome.
    Beckers RK; Selinger CI; Vilain R; Madore J; Wilmott JS; Harvey K; Holliday A; Cooper CL; Robbins E; Gillett D; Kennedy CW; Gluch L; Carmalt H; Mak C; Warrier S; Gee HE; Chan C; McLean A; Walker E; McNeil CM; Beith JM; Swarbrick A; Scolyer RA; O'Toole SA
    Histopathology; 2016 Jul; 69(1):25-34. PubMed ID: 26588661
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Claudin 4 expression in triple-negative breast cancer: correlation with androgen receptors and Ki-67 expression.
    Abd-Elazeem MA; Abd-Elazeem MA
    Ann Diagn Pathol; 2015 Feb; 19(1):37-42. PubMed ID: 25456318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [The characteristics of high density lipoprotein cholesterol and the relationship between high density lipoprotein cholesterol and the severity of coronary artery lesions in young men with acute myocardial infarction].
    Li Z; Tao Y; Huang J; Wang Q; Zhang DH; Wu XY
    Zhonghua Yi Xue Za Zhi; 2013 May; 93(19):1458-62. PubMed ID: 24029567
    [TBL] [Abstract][Full Text] [Related]  

  • 37. S100P and HYAL2 as prognostic markers for patients with triple-negative breast cancer.
    Maierthaler M; Kriegsmann M; Peng C; Jauch S; Szabo A; Wallwiener M; Rom J; Sohn C; Schneeweiss A; Sinn HP; Yang R; Burwinkel B
    Exp Mol Pathol; 2015 Aug; 99(1):180-7. PubMed ID: 26112095
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient survival and healthcare utilization costs after diagnosis of triple-negative breast cancer in a United States managed care cancer registry.
    Baser O; Wei W; Henk HJ; Teitelbaum A; Xie L
    Curr Med Res Opin; 2012 Mar; 28(3):419-28. PubMed ID: 22364568
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A single-nucleotide polymorphism in the 3'-UTR region of the adipocyte fatty acid binding protein 4 gene is associated with prognosis of triple-negative breast cancer.
    Wang W; Yuan P; Yu D; Du F; Zhu A; Li Q; Zhang P; Lin D; Xu B
    Oncotarget; 2016 Apr; 7(14):18984-98. PubMed ID: 26959740
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.
    Schmidt G; Gerlinger C; Juhasz-Böss I; Stickeler E; Rody A; Liedtke C; Wimberger P; Link T; Müller E; Fehm T; Abel M; Stein S; Bohle R; Endrikat J; Solomayer EF
    J Cancer Res Clin Oncol; 2016 Jun; 142(6):1369-76. PubMed ID: 27008006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.